Company news

Abeona Therapeutics Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Abeona Therapeutics Appoints Brian Pereira and Shawn Tomasello to the Board of Directors

April 20, 2020

Abeona Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

April 20, 2020

Abeona Therapeutics Stakeholder Letter in Response to the COVID-19 Pandemic

March 26, 2020

Abeona Therapeutics Announces First Patient Treated in Pivotal Phase III Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa

March 16, 2020

Abeona Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Business Updates

March 15, 2020

Abeona Therapeutics to Present at the 9th Annual SVB Leerink Global Healthcare Conference

February 25, 2020

Abeona Therapeutics Announces Positive Interim Data from MPS III Gene Therapy Programs Presented at WORLDSymposium™

February 11, 2020

Abeona Therapeutics Announces Participation in Inaugural World Congress on Epidermolysis Bullosa

January 20, 2020

Abeona Therapeutics Announces Issuance of U.S. Patent for AIM™ Capsids

January 14, 2020

Abeona Therapeutics Initiates Pivotal Phase 3 Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa

January 12, 2020

Abeona Announces Closing of $103.5 Million Underwritten Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

December 23, 2019

Abeona Therapeutics Receives European Medicines Agency PRIME Designation for ABO-102 Gene Therapy in MPS IIIA

December 19, 2019

Abeona Announces Pricing of Public Offering of Common Stock and Pre‑Funded Warrants

December 19, 2019

Abeona Therapeutics Announces Public Offering of Common Stock and Pre Funded Warrants

December 18, 2019

Abeona Therapeutics Cleared to Initiate Pivotal Phase 3 Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa

December 8, 2019

Abeona Therapeutics Reports Third Quarter 2019 Financial Results and Business Updates

November 11, 2019

Abeona Therapeutics Announces Presentations at the 27th European Society of Gene and Cell Therapy (ESGCT) Congress

October 20, 2019

Abeona Therapeutics Announces Publication of Positive Long-Term Data from Phase 1/2a Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa

October 14, 2019

Abeona Therapeutics Provides Regulatory Update Ahead of Pivotal Phase 3 Clinical Trial for EB-101 in Recessive Dystrophic Epidermolysis Bullosa

September 22, 2019

Abeona Therapeutics Receives FDA Fast Track Designation for ABO-101 for Treatment of Sanfilippo Syndrome Type B (MPS IIIB)

April 3, 2019

← Newer news releases

Calls

The 5 newest of 19 calls. Every call is listed under its year.

Decks

The 5 newest of 18 decks. Every deck is listed under its year.